EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates

Patrick Schöffski, Chao-Chi Wang, Morris Patrick Schöffski, Agnieszka Wozniak

Oncology Research and Treatment · 2024

DOI: 10.1159/000535491 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research and Treatment, 2024. Verfasst von Patrick Schöffski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Immunoconjugates, Antineoplastic Agents, Rhabdomyosarcoma. Die Arbeit wurde bisher 25-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Topoisomerase I is an enzyme that plays a crucial part in DNA replication and transcription by the relaxation of supercoiled double-stranded DNA. Topoisomerase I inhibitors bind to the topoisomerase I cleavage complex, thereby stabilizing it and preventing the religation of the DNA strands, leading to DNA damage, cell cycle arrest, and apoptosis. Various topoisomerase I inhibitors have been evaluated in solid tumors, and irinotecan and topotecan have been approved for the treatment of epithelial malignancies. None of them have been approved for sarcoma, a diverse group of rare solid tumors with an unmet need for effective treatments. Summary: Topoisomerase I inhibitors have been evaluated in preclinical studies as single agents or in combination in solid tumors, some of which have included sarcomas where activity was observed. Clinical trials evaluating topoisomerase I inhibitors for the treatment of sarcoma have shown limited efficacy as monotherapy. In combination with other cytotoxic agents, topoisomerase I inhibitors have become part of clinical routine in selected sarcoma subtypes. Regimens such as irinotecan/vincristine/temozolomide are used in relapsed rhabdomyosarcoma, irinotecan/temozolomide and vincristine/topotecan/cyclophosphamide are commonly given in refractory Ewing sarcoma, and topotecan/carboplatin showed some activity in advanced soft tissue sarcoma. This review provides an overview of key studies with topoisomerase I inhibitors for the treatment of sarcoma. Topoisomerase I inhibitors are currently also being assessed as “payloads” for antibody-drug conjugates (ADCs), allowing for the targeting of specific antigen-expressing tumor cells and the delivery of the inhibitor directly to the tumor cells with the potential of enhancing therapeutic efficacy while minimizing systemic toxicity. Here, we also provide a brief overview on topoisomerase I-ADCs. Key Message: Topoisomerase I inhibitors are an important component of some systemic therapies for selected sarcomas and have potent cytotoxic properties and pharmacological characteristics that make them relevant candidates as payloads for the development of sarcoma-specific ADCs. ADCs are antibody-based targeted agents allowing for efficient and specific delivery of a given drug to the tumor cell. Topoisomerase I-ADCs are a novel targeted delivery approach which may have the potential to improve the therapeutic index of topoisomerase I inhibitors in the treatment of sarcoma and warrants investigation in a broad variety of mesenchymal malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesAntineoplastic AgentsRhabdomyosarcomaHumansTopoisomerase I InhibitorsIrinotecanTopotecanDNA Topoisomerases, Type IVincristineTemozolomideNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Antibody-drug conjugatesCytotoxic payloadSarcomaSystemic therapyTopoisomerase I inhibitors

Substanzen

Topoisomerase I InhibitorsIrinotecanTopotecanDNA Topoisomerases, Type IVincristineTemozolomideImmunoconjugatesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  • Department of Oncology, Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium.

Zitieren

APA

Schöffski, P., Wang, C. C., Schöffski, M. P., & Wozniak, A. (2024). Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates. Oncology Research and Treatment. https://doi.org/10.1159/000535491

Vancouver

Schöffski P, Wang CC, Schöffski MP, Wozniak A. Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates. Oncology Research and Treatment. 2024. doi:10.1159/000535491

BibTeX
@article{Schffski2024,
  author = {Schöffski, Patrick and Wang, Chao-Chi and Schöffski, Morris Patrick and Wozniak, Agnieszka},
  title = {Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates},
  journal = {Oncology Research and Treatment},
  year = {2024},
  doi = {10.1159/000535491}
}
Kostenlos starten →